Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy

Marylou Cardenas-Turanzas, Farhad Ravandi-Kashani, Jorge E. Cortes, Elias Jabbour, Stefan Faderl, Sherry A. Pierce, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Background: Patients with AML and refractory disease receive investigational therapies within 2 months of their death. The attribution of serious AEs in this phase to disease progression vs. drug toxicity is tenuous. We aimed to determine the incidence of serious AEs in the last 2 weeks of life of patients with refractory-relapsed AML undergoing salvage therapy (ST). Patients and Methods: Adults who received ST from September 2010 to December 2011 were evaluated. Data collected included incidence of serious AEs, type of ST, medical complications, length of hospital stay, and Intensive Care Unit stays, organ dysfunctions, and use of life support therapies. Results: A total of 122 patients received ST. Most 64 patients (52%) received intensive chemotherapy; 39 patients (32%) had single investigational drug therapies, and 19 patients (16%) received therapy with hypomethylating agents. Common complications were pneumonia (82%), disseminated intravascular coagulopathy 72 patients (59%), and septic shock 60 patients (49%). Notable complications included: acute respiratory failure justifying invasive mechanical ventilation in 60 patients (42%), renal failure requiring dialysis in 33 patients (27%), atrial fibrillation in 37 patients (30%), and prolonged prothrombin time (grade 3) in 68 patients (56%). There was no difference in the incidence of these complications by type of ST. Conclusions: Baseline expectations of serious AEs at the end of life of patients with AML undergoing ST were established. The AE profiles of new investigational interventions or therapies could be compared with what would be expected in such circumstances from the combined effect of disease progression, expected complications of the AML therapy, and therapies delivered in previous historical contexts.

Original languageEnglish (US)
Pages (from-to)579-583
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number5
DOIs
StatePublished - Oct 1 2013
Externally publishedYes

Fingerprint

Salvage Therapy
Acute Myeloid Leukemia
Investigational Therapies
Disease Progression
Length of Stay
Incidence
Investigational Drugs
Therapeutics
Drug Therapy
Prothrombin Time
Septic Shock
Drug-Related Side Effects and Adverse Reactions
Artificial Respiration
Respiratory Insufficiency
Atrial Fibrillation
Renal Insufficiency

Keywords

  • Adverse effects
  • Cancer chemotherapy agents
  • Drug toxicities
  • Leukemias
  • Terminally ill

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. / Cardenas-Turanzas, Marylou; Ravandi-Kashani, Farhad; Cortes, Jorge E.; Jabbour, Elias; Faderl, Stefan; Pierce, Sherry A.; Kantarjian, Hagop.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 5, 01.10.2013, p. 579-583.

Research output: Contribution to journalArticle

Cardenas-Turanzas, Marylou ; Ravandi-Kashani, Farhad ; Cortes, Jorge E. ; Jabbour, Elias ; Faderl, Stefan ; Pierce, Sherry A. ; Kantarjian, Hagop. / Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13, No. 5. pp. 579-583.
@article{31f45efdce1b4723b78f89aef50d2d75,
title = "Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy",
abstract = "Background: Patients with AML and refractory disease receive investigational therapies within 2 months of their death. The attribution of serious AEs in this phase to disease progression vs. drug toxicity is tenuous. We aimed to determine the incidence of serious AEs in the last 2 weeks of life of patients with refractory-relapsed AML undergoing salvage therapy (ST). Patients and Methods: Adults who received ST from September 2010 to December 2011 were evaluated. Data collected included incidence of serious AEs, type of ST, medical complications, length of hospital stay, and Intensive Care Unit stays, organ dysfunctions, and use of life support therapies. Results: A total of 122 patients received ST. Most 64 patients (52{\%}) received intensive chemotherapy; 39 patients (32{\%}) had single investigational drug therapies, and 19 patients (16{\%}) received therapy with hypomethylating agents. Common complications were pneumonia (82{\%}), disseminated intravascular coagulopathy 72 patients (59{\%}), and septic shock 60 patients (49{\%}). Notable complications included: acute respiratory failure justifying invasive mechanical ventilation in 60 patients (42{\%}), renal failure requiring dialysis in 33 patients (27{\%}), atrial fibrillation in 37 patients (30{\%}), and prolonged prothrombin time (grade 3) in 68 patients (56{\%}). There was no difference in the incidence of these complications by type of ST. Conclusions: Baseline expectations of serious AEs at the end of life of patients with AML undergoing ST were established. The AE profiles of new investigational interventions or therapies could be compared with what would be expected in such circumstances from the combined effect of disease progression, expected complications of the AML therapy, and therapies delivered in previous historical contexts.",
keywords = "Adverse effects, Cancer chemotherapy agents, Drug toxicities, Leukemias, Terminally ill",
author = "Marylou Cardenas-Turanzas and Farhad Ravandi-Kashani and Cortes, {Jorge E.} and Elias Jabbour and Stefan Faderl and Pierce, {Sherry A.} and Hagop Kantarjian",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.clml.2013.03.021",
language = "English (US)",
volume = "13",
pages = "579--583",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "5",

}

TY - JOUR

T1 - Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy

AU - Cardenas-Turanzas, Marylou

AU - Ravandi-Kashani, Farhad

AU - Cortes, Jorge E.

AU - Jabbour, Elias

AU - Faderl, Stefan

AU - Pierce, Sherry A.

AU - Kantarjian, Hagop

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background: Patients with AML and refractory disease receive investigational therapies within 2 months of their death. The attribution of serious AEs in this phase to disease progression vs. drug toxicity is tenuous. We aimed to determine the incidence of serious AEs in the last 2 weeks of life of patients with refractory-relapsed AML undergoing salvage therapy (ST). Patients and Methods: Adults who received ST from September 2010 to December 2011 were evaluated. Data collected included incidence of serious AEs, type of ST, medical complications, length of hospital stay, and Intensive Care Unit stays, organ dysfunctions, and use of life support therapies. Results: A total of 122 patients received ST. Most 64 patients (52%) received intensive chemotherapy; 39 patients (32%) had single investigational drug therapies, and 19 patients (16%) received therapy with hypomethylating agents. Common complications were pneumonia (82%), disseminated intravascular coagulopathy 72 patients (59%), and septic shock 60 patients (49%). Notable complications included: acute respiratory failure justifying invasive mechanical ventilation in 60 patients (42%), renal failure requiring dialysis in 33 patients (27%), atrial fibrillation in 37 patients (30%), and prolonged prothrombin time (grade 3) in 68 patients (56%). There was no difference in the incidence of these complications by type of ST. Conclusions: Baseline expectations of serious AEs at the end of life of patients with AML undergoing ST were established. The AE profiles of new investigational interventions or therapies could be compared with what would be expected in such circumstances from the combined effect of disease progression, expected complications of the AML therapy, and therapies delivered in previous historical contexts.

AB - Background: Patients with AML and refractory disease receive investigational therapies within 2 months of their death. The attribution of serious AEs in this phase to disease progression vs. drug toxicity is tenuous. We aimed to determine the incidence of serious AEs in the last 2 weeks of life of patients with refractory-relapsed AML undergoing salvage therapy (ST). Patients and Methods: Adults who received ST from September 2010 to December 2011 were evaluated. Data collected included incidence of serious AEs, type of ST, medical complications, length of hospital stay, and Intensive Care Unit stays, organ dysfunctions, and use of life support therapies. Results: A total of 122 patients received ST. Most 64 patients (52%) received intensive chemotherapy; 39 patients (32%) had single investigational drug therapies, and 19 patients (16%) received therapy with hypomethylating agents. Common complications were pneumonia (82%), disseminated intravascular coagulopathy 72 patients (59%), and septic shock 60 patients (49%). Notable complications included: acute respiratory failure justifying invasive mechanical ventilation in 60 patients (42%), renal failure requiring dialysis in 33 patients (27%), atrial fibrillation in 37 patients (30%), and prolonged prothrombin time (grade 3) in 68 patients (56%). There was no difference in the incidence of these complications by type of ST. Conclusions: Baseline expectations of serious AEs at the end of life of patients with AML undergoing ST were established. The AE profiles of new investigational interventions or therapies could be compared with what would be expected in such circumstances from the combined effect of disease progression, expected complications of the AML therapy, and therapies delivered in previous historical contexts.

KW - Adverse effects

KW - Cancer chemotherapy agents

KW - Drug toxicities

KW - Leukemias

KW - Terminally ill

UR - http://www.scopus.com/inward/record.url?scp=84884155640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884155640&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.03.021

DO - 10.1016/j.clml.2013.03.021

M3 - Article

C2 - 23763918

AN - SCOPUS:84884155640

VL - 13

SP - 579

EP - 583

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 5

ER -